logo-loader

Clinigen Group sees significant opportunities with Proleukin acquisition

Published: 20:37 17 Jul 2018 AEST

Shaun Chilton, chief executive of Clinigen Group PLC (LON:CLIN), discusses with Proactive's Andrew Scott the speciality pharma company's decision to acquire the global rights to Proleukin for an undisclosed sum from Novartis.

The drug is used to treat the metastatic forms of renal cell carcinoma and melanoma and the plan is to work with the healthcare professionals to revitalise the product.

Updating on recent trading, Chilton says revenues for the year ended June 30 grew by 27% on a constant currency basis, while gross profit advanced by 16% on the same measurement.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

6 hours, 3 minutes ago